[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620049":3},{"organization":4,"armGroups":7,"interventions":49,"overallOfficials":162,"centralContacts":166,"locations":175,"responsibleParty":188,"collaborators":54,"id":190,"slug":191,"hasResults":192,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":54,"eligibilityCriteria":196,"healthyVolunteers":192,"sex":197,"minAge":198,"maxAge":54,"enrollmentInfo":199,"targetDuration":54,"studyType":202,"phases":203,"briefSummary":205,"conditions":206,"keywords":54,"overallStatus":209,"whyStopped":54,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":218,"locationsCount":219},{"fullName":5,"class":6},"University of California, San Francisco","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"In situ cutaneous microdevice","EXPERIMENTAL","The small device, about the size of a grain of rice, has up to 20 tiny reservoirs that hold medications that are approved by the Food and Drug Administration (FDA) for atopic dermatitis and psoriasis. Very small amounts of these medications will be released into the skin (at levels in your body much lower than are typically used). In this study, the device will be tested to see if it's safe and works well for predicting how the skin will react to standard treatments. We will also look at how these reactions are connected to genetic information and overall treatment results.",[13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48],"Device: In situ cutaneous microdevice","Drug: Triamcinolone","Drug: 5-Fluorouracil","Drug: Calcipotriene","Drug: Tapinarof","Drug: Crisaborole","Drug: Tacrolimus","Drug: Adalimumab","Drug: Etanercept","Drug: Certolizumab","Drug: Infliximab","Drug: Secukinumab","Drug: Ixekizumab","Drug: Apremilast","Drug: Risankizumab","Drug: Ustekinumab","Drug: Hydroxychloroquine","Drug: Methotrexate","Drug: Mycophenolate","Drug: Azathioprine","Drug: Chloroquine","Drug: Cyclosporine","Drug: Tofacitinib","Drug: Deucravacitinib","Drug: Dupilumab","Drug: Tralokinumab","Drug: Guselkumab","Drug: Tildrakizumab","Drug: Baractinib","Drug: Abrocitinib","Drug: Upadacitinib","Drug: Lebrikizumab","Drug: Nemolizumab","Drug: Ruxolitinib","Drug: Bimekizumab","Drug: Roflumilast",[50,55,59,63,66,69,72,75,78,81,84,87,90,93,96,99,102,105,108,111,114,117,120,123,126,129,132,135,138,141,144,147,150,153,156,159],{"type":51,"name":9,"description":52,"armGroupLabels":53,"otherNames":54},"DEVICE","The small device, about the size of a grain of rice, has up to 20 tiny reservoirs that hold medications that are approved by the Food and Drug Administration (FDA) for atopic dermatitis and psoriasis. In this study, the device will be tested to see if it's safe and works well for predicting how the skin will react to standard treatments. The microdevice will contain a subset of the following: Triamcinolone, 5-fluorouracil, Calcipotriene, Tapinarof, Crisaborole, Tacrolimus, Adalimumab, Etanercept, Certolizumab, Infliximab, Secukinumab, Ixekizumab, Apremilast, Risankizumab, Ustekinumab, Hydroxychloroquine, Methotrexate, Mycophenolate, Azathioprine, Chloroquine, Cyclosporine, Tofacitinib, Deucravacitinib, Dupilumab, Tralokinumab, Guselkumab, Tildrakizumab, Baractinib, Abrocitinib, Upadacitinib, Lebrikizumab, Nemolizumab, Ruxolitinib, Bimekizumab, Roflumilast.",[9],null,{"type":56,"name":57,"description":57,"armGroupLabels":58,"otherNames":54},"DRUG","Triamcinolone",[9],{"type":56,"name":60,"description":61,"armGroupLabels":62,"otherNames":54},"5-Fluorouracil","5-fluorouracil",[9],{"type":56,"name":64,"description":64,"armGroupLabels":65,"otherNames":54},"Calcipotriene",[9],{"type":56,"name":67,"description":67,"armGroupLabels":68,"otherNames":54},"Tapinarof",[9],{"type":56,"name":70,"description":70,"armGroupLabels":71,"otherNames":54},"Crisaborole",[9],{"type":56,"name":73,"description":73,"armGroupLabels":74,"otherNames":54},"Tacrolimus",[9],{"type":56,"name":76,"description":76,"armGroupLabels":77,"otherNames":54},"Adalimumab",[9],{"type":56,"name":79,"description":79,"armGroupLabels":80,"otherNames":54},"Etanercept",[9],{"type":56,"name":82,"description":82,"armGroupLabels":83,"otherNames":54},"Certolizumab",[9],{"type":56,"name":85,"description":85,"armGroupLabels":86,"otherNames":54},"Infliximab",[9],{"type":56,"name":88,"description":88,"armGroupLabels":89,"otherNames":54},"Secukinumab",[9],{"type":56,"name":91,"description":91,"armGroupLabels":92,"otherNames":54},"Ixekizumab",[9],{"type":56,"name":94,"description":94,"armGroupLabels":95,"otherNames":54},"Apremilast",[9],{"type":56,"name":97,"description":97,"armGroupLabels":98,"otherNames":54},"Risankizumab",[9],{"type":56,"name":100,"description":100,"armGroupLabels":101,"otherNames":54},"Ustekinumab",[9],{"type":56,"name":103,"description":103,"armGroupLabels":104,"otherNames":54},"Hydroxychloroquine",[9],{"type":56,"name":106,"description":106,"armGroupLabels":107,"otherNames":54},"Methotrexate",[9],{"type":56,"name":109,"description":109,"armGroupLabels":110,"otherNames":54},"Mycophenolate",[9],{"type":56,"name":112,"description":112,"armGroupLabels":113,"otherNames":54},"Azathioprine",[9],{"type":56,"name":115,"description":115,"armGroupLabels":116,"otherNames":54},"Chloroquine",[9],{"type":56,"name":118,"description":118,"armGroupLabels":119,"otherNames":54},"Cyclosporine",[9],{"type":56,"name":121,"description":121,"armGroupLabels":122,"otherNames":54},"Tofacitinib",[9],{"type":56,"name":124,"description":124,"armGroupLabels":125,"otherNames":54},"Deucravacitinib",[9],{"type":56,"name":127,"description":127,"armGroupLabels":128,"otherNames":54},"Dupilumab",[9],{"type":56,"name":130,"description":130,"armGroupLabels":131,"otherNames":54},"Tralokinumab",[9],{"type":56,"name":133,"description":133,"armGroupLabels":134,"otherNames":54},"Guselkumab",[9],{"type":56,"name":136,"description":136,"armGroupLabels":137,"otherNames":54},"Tildrakizumab",[9],{"type":56,"name":139,"description":139,"armGroupLabels":140,"otherNames":54},"Baractinib",[9],{"type":56,"name":142,"description":142,"armGroupLabels":143,"otherNames":54},"Abrocitinib",[9],{"type":56,"name":145,"description":145,"armGroupLabels":146,"otherNames":54},"Upadacitinib",[9],{"type":56,"name":148,"description":148,"armGroupLabels":149,"otherNames":54},"Lebrikizumab",[9],{"type":56,"name":151,"description":151,"armGroupLabels":152,"otherNames":54},"Nemolizumab",[9],{"type":56,"name":154,"description":154,"armGroupLabels":155,"otherNames":54},"Ruxolitinib",[9],{"type":56,"name":157,"description":157,"armGroupLabels":158,"otherNames":54},"Bimekizumab",[9],{"type":56,"name":160,"description":160,"armGroupLabels":161,"otherNames":54},"Roflumilast",[9],[163],{"name":164,"affiliation":5,"role":165},"Raymond Cho, MD, PhD","PRINCIPAL_INVESTIGATOR",[167,171],{"name":164,"role":168,"phone":169,"phoneExt":54,"email":170},"CONTACT","415-353-7800","raymond.cho@ucsf.edu",{"name":172,"role":168,"phone":173,"phoneExt":54,"email":174},"Jeffrey Cheng, MD, PhD","415-575-0524","jeffrey.cheng@ucsf.edu",[176],{"facility":5,"status":54,"city":177,"state":178,"zip":179,"country":180,"countryCode":181,"cosmosGeoPoint":182,"geoPoint":187,"contacts":54},"San Francisco","California","94158","United States","US",{"type":183,"coordinates":184},"Point",[185,186],-122.41942,37.77493,{"lat":186,"lon":185},{"type":189,"investigatorFullName":54,"investigatorTitle":54,"investigatorAffiliation":54,"oldNameTitle":54,"oldOrganization":54},"SPONSOR","100620049","phase-4-utilization-of-a-microdevice-for-psoriasis-and-atopic-dermatitis-100620049",false,"NCT07352566","Utilization of a Microdevice for Psoriasis and Atopic Dermatitis","Utilization of a Cutaneous Therapy In Situ Microdevice","Inclusion Criteria:\n\n\\> 18 years of age patients with atopic dermatitis or psoriasis if female patient with child bearing potential (on oral contraceptive pills or intrauterine device for at least 30 days)\n\nExclusion Criteria: None","ALL","18 Years",{"count":200,"type":201},10,"ESTIMATED","INTERVENTIONAL",[204],"PHASE4","This study is being done to test a microdevice, which is a small device designed to test drugs directly on skin conditions like atopic dermatitis (eczema) and psoriasis.\n\nThe small device, about the size of a grain of rice, has up to 20 tiny reservoirs that hold medications that are approved by the Food and Drug Administration (FDA) for atopic dermatitis and psoriasis. Very small amounts of these medications will be released into the skin (at levels in your body much lower than are typically used). In this study, the device will be tested to see if it's safe and works well for predicting how the skin will react to standard treatments. We will also look at how these reactions are connected to genetic information and overall treatment results.",[207,208],"Psoriasis","Atopic Dermatitis","NOT_YET_RECRUITING","2026-06-01",{"date":212,"type":213},"2026-06-03","ACTUAL",{"date":215,"type":201},"2026-08-01",{"date":217,"type":201},"2030-06-01",{"name":5,"class":6},1]